Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells

Blood

Volumn 121, Issue 17, 2013, Pages 3413-3419

  Walker, Brian A ^a   Wardell, Christopher P ^a   Johnson, David C ^a   Kaiser, Martin F ^a   Begum, Dil B ^a   Dahir, Nasrin B ^a   Ross, Fiona M ^b   Davies, Faith E ^a   Gonzalez, David ^a   Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b SALISBURY DISTRICT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ATP6V1G1P1 PROTEIN; CYCLIN D1; CYCLIN D3; DHX35 PROTEIN; DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IMMUNOGLOBULIN HEAVY CHAIN; MMSET PROTEIN; MYEOV PROTEIN; PEPTIDES AND PROTEINS; RNA; SYNDECAN 1; TAF8 PROTEIN; TPCN2 PROTEIN; TRANSCRIPTION FACTOR MAF; TRANSCRIPTION FACTOR MAFB; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UBR2 PROTEIN; UNCLASSIFIED DRUG; WWOX PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; BONE MARROW; CHROMOSOME 11; CHROMOSOME 14; CHROMOSOME 16; CHROMOSOME 20; CHROMOSOME 4; CHROMOSOME 6; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION; CPG ISLAND; DHJH RECOMBINATION; DNA STRUCTURE; DOUBLE STRANDED DNA BREAK; ENHANCER REGION; GENE ACTIVATION; GENE LOCUS; GENE REARRANGEMENT; GENETIC RECOMBINATION; GERMINAL CENTER; HOMOLOGOUS RECOMBINATION; HUMAN; MASSIVELY PARALLEL SEQUENCING; MULTIPLE MYELOMA; MUTATIONAL ANALYSIS; PRE B LYMPHOCYTE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOMATIC HYPERMUTATION; VDJ RECOMBINATION; WGCW MOTIF; GENE TRANSLOCATION; GENETICS; METABOLISM; PATHOLOGY; PLASMA CELL; POLYMERASE CHAIN REACTION;

BONE MARROW; CHROMOSOME BREAKAGE; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 20; DNA, NEOPLASM; GERMINAL CENTER; HOMOLOGOUS RECOMBINATION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MULTIPLE MYELOMA; PLASMA CELLS; POLYMERASE CHAIN REACTION; PRECURSOR CELLS, B-LYMPHOID; TRANSLOCATION, GENETIC;

MLCS; MLOWN;

EID: 84879399749     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-471888     Document Type: Article

References (30)

1. Richardson C, Jasin M. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature. 2000;405(6787):697-700.
2. Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122(10):3416-3423.
3. González D, van der Burg M, García-Sanz R, et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood. 2007;110(9):3112-3121.
4. Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood. 1992;80(9):2326-2335.
5. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA. 1996; 93(24):13931-13936.
6. Pratt G, Fenton JA, Proffitt JA, et al. True spectrum of 14q32 translocations in multiple myeloma. Br J Haematol. 1998;103(4): 1209-1210.
7. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335-348.
8. Boersma-Vreugdenhil GR, Kuipers J, Van Stralen E, et al. The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint. Br J Haematol. 2004; 126(3):355-363.
9. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood. 1996;88(2):674-681.
10. Chesi M, Bergsagel PL, Shonukan OO, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood. 1998;91(12): 4457-4463.
11. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997;16(3):260-264.
12. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92(9):3025-3034.
13. Kozarewa I, Rosa-Rosa JM, Wardell CP, et al. A modified method for whole exome resequencing from minimal amounts of starting DNA [published correction appears in PLoS One. 2012;7(4)]. PLoS ONE. 2012;7(3):e32617.
14. Chiecchio L, Protheroe RK, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006;20(9): 1610-1617.
15. Ross FM, Ibrahim AH, Vilain-Holmes A, et al; UK Myeloma Forum. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia. 2005;19(9): 1634-1642.
16. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008; 36(Web Server issue):W503–W508.
17. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20(40):5611-5622.
18. Greisman HA, Lu Z, Tsai AG, Greiner TC, Yi HS, Lieber MR. IgH partner breakpoint sequences provide evidence that AID initiates t(11;14) and t(8;14) chromosomal breaks in mantle cell and Burkitt lymphomas. Blood. 2012;120(14): 2864-2867.
19. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101(4):1520-1529.
20. Walker BA, Leone PE, Chiecchio L, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15): e56-e65.
21. Welzel N, Le T, Marculescu R, et al. Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res. 2001;61(4): 1629-1636.
22. Williams ME, Swerdlow SH, Meeker TC. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. Leukemia. 1993; 7(9):1437-1440.
23. Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101(12):4975-4981.
24. Boyd KD, Ross FM, Chiecchio L, et al; NCRI Haematology Oncology Studies Group. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26(2):349-355.
25. Ross FM, Chiecchio L, Dagrada G, et al; UK Myeloma Forum. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica. 2010; 95(7):1221-1225.
26. Stralen E, Leguit RJ, Begthel H, et al. MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple myeloma patients. Leukemia. 2009;23(4):801-803.
27. Jenner MW, Leone PE, Walker BA, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007;110(9): 3291-3300.
28. Paige AJ, Taylor KJ, Taylor C, et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA. 2001;98(20): 11417-11422.
29. Smith DI, McAvoy S, Zhu Y, Perez DS. Large common fragile site genes and cancer. Semin Cancer Biol. 2007;17(1):31-41.
30. Kaiser MF, Walker BA, Hockley SL, et al. A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR [published online ahead of print January 15, 2013]. Leukemia.